Vico Therapeutics

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for severe neurological diseases. Their lead product candidate, VO659, is in Phase 1/2a clinical development for spinocerebellar ataxia types 3 and 1, and Huntington's disease. Vico's research platform designs ASOs to target genetic neurological diseases.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $60M

Date: 05-Jan-2024

Investors: Ackermans & van Haaren, Droia Ventures, EQT Life Sciences, Kurma Partners, Polaris Partners, Pureos Bioventures, Eurazeo

Markets: Biotechnology, Genetic Medicines, Neurological Diseases

HQ: Leiden, South Holland, Netherlands

Founded: 2019

Website: https://www.vicotx.com

LinkedIn: https://www.linkedin.com/company/vico-therapeutics/

Twitter: https://twitter.com/VicoThera

Instagram: